GlaxoSmithKline Q3 Results - Q3 Top Pharma Company Earnings Reports

View GlaxoSmithKline's Q3 Earnings Report

FiercePharma says: Emerging markets are paying off for GlaxoSmithKline, but it's pandemic flu that's really accelerating sales. Third-quarter profits jumped by 30 percent to £1.34 billion ($2.18 billion), partly on currency effects, while sales grew 15 percent to £6.76 billion ($11.05 billion). Read more...


  • Return to sales growth with Q3 turnover +3% CER; +15% sterling
  • Continued improvement expected in Q4
  • Portfolio diversification and investment in key areas drives return to sales growth: Emerging Markets (+25%); Japan (+19%) and Consumer Healthcare (+8%)
  • Further growth expected in Q4 2009 including significant sales of influenza products
  • US sales -12% primarily due to continued adverse impact of generic competition

Check out GSK's current estimates from CNN Money

GSK's Website:

GlaxoSmithKline Q3 Results - Q3 Top Pharma Company Earnings Reports

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.